Center For Information And Study On Clinical Research Participation
Center For Information And Study On Clinical Research Participation is recorded as a service provider in 60 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 60 trials · Latest update first
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
An open-label, single-arm study evaluating the activity, safety, and pharmacokinetics of rozanolixizumab in pediatric study participants with moderate to severe generalized myasthenia gravis
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
A Multicentre, Randomised, Double-Blind, Parallel-Group Placebo-Controlled, Phase 3, Efficacy and Safety Study of Tezepelumab in 5 to < 12 Year Old Children with Severe Uncontrolled Asthma (HORIZON)
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults with IgA Nephropathy (The BEYOND Study)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A prospective, open-label, single-arm, multicenter pharmacokinetic study evaluating the placental transfer of dapirolizumab pegol to the infant(s) from pregnant study participants with active systemic lupus erythematosus who are administered dapirolizumab pegol
Sponsor UCB Biopharma
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
A multicenter, open-label, prospective study to assess the concentration of bimekizumab in mature breast milk from mothers receiving treatment with Bimzelx® (bimekizumab)
Sponsor UCB Biopharma
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study with Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit from Continued Treatment
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
C6461003 - AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 3 randomized, double-blind, placebo-controlled, parallel group, multicenter study with open-label extension to evaluate the efficacy and safety of fenfluramine hydrochloride in study participants with Rett syndrome
Sponsor UCB Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe Hemophilia B
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
BRISOTE: A Multicentre, Randomised, Double-blind, Parallel Group, Active-Controlled, Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium-Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
A phase 3, randomized, double-blind, placebo-controlled, multicenter study with open-label extension to evaluate the efficacy and safety of bimekizumab in study participants with palmoplantar pustulosis
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
A Phase II, Open-label, Single-arm Study of Osimertinib as Induction Therapy Prior to CRT and Maintenance Osimertinib in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Stage III, Unresectable Non-small Cell Lung Cancer (NEOLA)
Sponsor Astrazeneca AB
- Start (EU)
- Latest update
- Estimated end
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF GALVOKIMIG IN ADULT STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rozanolixizumab in adult participants with ocular myasthenia gravis
Sponsor UCB Biopharma
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 1, Single Dose, Non-Randomised, Multicentre, Open‑Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) in Post-menopausal Female Subjects
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- The study was conducted in the United States, Bulgaria, and Slovakia from 20 February 2023 to 22 February 2024.
- A 19 April 2023 substantial protocol amendment clarified safety and tolerability endpoints and added safety/tolerability stopping rules.
These findings describe the trial, not the service provider’s performance or responsibility.
Questions about this trial experience
What services are recorded for Center For Information And Study On Clinical Research Participation?
The 2026-10-09 snapshot links Center For Information And Study On Clinical Research Participation to 60 distinct CTIS trials. Recorded services include Medical writing, Patient Engagement Materials, Clinical Trials Transparency (Patient communication), CTT-PE, among 23 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Center For Information And Study On Clinical Research Participation?
The most frequently recorded therapeutic areas are Immunology, Neurology, Rheumatology, Solid Tumor Oncology. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Center For Information And Study On Clinical Research Participation conducted?
The linked trials record locations in 24 countries, including Spain, Germany, Italy, Poland, France. These are trial locations, not confirmed office locations or countries where Center For Information And Study On Clinical Research Participation delivered services.
What can this page tell me about Center For Information And Study On Clinical Research Participation's trial experience?
Browse 60 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Center For Information And Study On Clinical Research Participation. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Center For Information And Study On Clinical Research Participation Inc.